50.4%$2.17B38%
Dupixent Sales Drive Sanofi Collaboration Revenue
Sanofi collaboration revenue rose 50.4% YoY to $2.17B in Q2 FY2026, supported by a 38% YoY surge in global net sales of Dupixent to $6.00B.
Source: 10-Q Item 2 MD&A, p.26, 36
A fixed rule set over this filing's XBRL figures and the number of high-severity risks found in it — no model judgement.
Not investment advice and not a price target: it scores the quarter's fundamentals, not the stock. Full methodology →
AI Takeaway
In Q2 FY2026, Regeneron generated $4.29B in revenue, up 16.7% YoY, driven by strong Dupixent collaboration revenue and EYLEA HD growth, despite persistent competitive pressures on legacy EYLEA and a 6.8% decline in net income to $1.30B.
Revenue
$4.29B
+16.73% YoY
EPS (Diluted)
$12.23
-4.53% YoY
Operating Income
$1.29B
+19.82% YoY
Filed · Source: SEC EDGAR 10-Q filing
Regeneron Pharmaceuticals (REGN) reported Q2 FY2026 revenue of $4.29B, up 16.7% year over year. The company posted net income of $1.3B, down 6.8% from a year earlier, with diluted EPS of $12.23. Operating income was $1.29B, up 19.8% year over year. REGN's fiscal Q2 FY2026 corresponds to calendar Q2 2026.
Regeneron reported Q2 FY2026 revenue of $4.29B (+16.7% YoY) and net income of $1.30B (-6.8% YoY), backed by strong Dupixent and EYLEA HD momentum.
Last 4 quarters: 4 beats
Sanofi collaboration revenue rose 50.4% YoY to $2.17B in Q2 FY2026, supported by a 38% YoY surge in global net sales of Dupixent to $6.00B.
Source: 10-Q Item 2 MD&A, p.26, 36
EYLEA HD U.S. net sales increased 52% YoY to $596.3M, partially offsetting a 45% YoY decline in legacy U.S. EYLEA sales ($412.2M) caused by market transition to EYLEA HD and increasing biosimilar competition.
Source: 10-Q Item 2 MD&A, p.26, 36
In April 2026, Regeneron finalized agreements with the U.S. government establishing Most-Favored-Nation Pricing for select Medicaid products, joining TrumpRx.gov, offering Otarmeni free of charge, and securing tariff protection through January 2029 tied to domestic R&D and manufacturing investments.
Source: 10-Q Item 2 MD&A, p.34
Regeneron expanded its external pipeline with strategic deals, including a $125.0M combined upfront/equity investment with Parabilis Medicines in May 2026 and a $150.0M agreement with Tessera Therapeutics in January 2026.
Source: 10-Q Item 2 MD&A, p.35
Regeneron relies heavily on EYLEA HD, EYLEA, and Dupixent revenues. The loss of market share for legacy EYLEA due to biosimilar entry and compounding alternatives may harm total revenue if EYLEA HD adoption does not fully compensate.
Source: 10-Q Item 1A, p.46
Government price control initiatives, Medicare and Medicaid reimbursement policy changes, and terms under the April 2026 U.S. Government Agreements could reduce net realized prices across key commercial products.
Source: 10-Q Item 1A, p.46-48
Drug discovery and development involve significant capital costs and uncertainty, highlighted by recent failures in Phase 3 trials such as fianlimab in first-line metastatic melanoma and the discontinuation of itepekimab in COPD.
Source: 10-Q Item 1A, p.34, 44
This analysis does not extract a guidance section. Companies issue revenue and EPS outlook in the 8-K press release and on the earnings call rather than in the 10-Q itself — though the filing's management discussion can contain forward-looking statements, which appear in the highlights above where they were material.
See the REGN earnings preview — expected date, analyst estimates and what to watch →
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.29B | $3.68B | +16.73% |
Operating Income | $1.29B | $1.08B | +19.82% |
Net Income | $1.3B | $1.39B | -6.81% |
EPS (Basic) | $12.62 | $13.24 | -4.68% |
EPS (Diluted) | $12.23 | $12.81 | -4.53% |
R&D Expense | $1.63B | $1.42B | +14.76% |
SG&A Expense | $662.1M | $634.2M | +4.40% |
Regeneron reported total revenue of $4.29B in Q2 FY2026, a 16.7% increase compared to $3.68B in Q2 FY2025. Growth was primarily driven by higher collaboration revenues from Sanofi for Dupixent.
Combined U.S. sales of EYLEA and EYLEA HD were $1.01B in Q2 FY2026. EYLEA HD sales expanded 52% YoY to $596.3M, while legacy EYLEA sales dropped 45% YoY to $412.2M due to biosimilar competition and patient transition to EYLEA HD.
Regeneron achieved 16.7% revenue growth to $4.29B and increased operating income by 19.8% to $1.29B. However, net income decreased 6.8% YoY to $1.30B due to higher income tax expenses and lower non-operating income.
Regeneron highlighted market competition and biosimilars impacting the EYLEA franchise, potential pricing pressures under government drug agreements, and clinical trial development risks as primary uncertainties.
Expected release date, analyst estimates & what to watch
Regeneron delivered strong Q1 2026 revenue growth of 19.0% YoY to $3.61B, driven by robust product demand, but net income declined 10.1% to $727.2M as R&D spending surged 16.3% and current liabilities jumped 43.2%.
Regeneron delivered modest FY2025 revenue growth of 1.0% to $14.3B, but operating income fell 10.3% as R&D spending surged 14.0% to $5.85B, while strong operating cash flow of $4.98B and robust capital returns underscored the company's financial resilience.
Other companies in Biotechnology